Vice Chairwoman and General Manager Sarina Lin Invited to Share Global Expansion Experience, Advancing Next-Generation ADC/ARC Development
Honeybear Biosciences has been dedicated to the development of next-generation Antibody-Drug Conjugates (ADCs) and Antibody-Radionuclide Conjugates (ARCs) by integrating the expertise of internationally renowned, cross-disciplinary scientists and industry experts. On July 16, 2026, during BioAsia, Sarina Lin, Vice Chairwoman and General Manager, was invited to speak at the International Market Expansion Forum for Biomedical Startups, where she shared Honeybear Biosciences’ experience in global market expansion and discussed the company’s international growth strategy and achievements.
Facing an increasingly competitive global biopharmaceutical landscape, Honeybear Biosciences has adopted a global market-oriented strategy from its inception. Leveraging its proprietary technology platform, a world-class international advisory team, multi-channel clinical collaborations, and active participation in leading global biotechnology conferences, the company has enhanced its international visibility through scientific presentations, business partnering activities, and targeted media outreach. These efforts have brought both Honeybear Biosciences and its award-winning CoNectar® proprietary platform to the attention of the global biotechnology community, enabling the company to expand onto the international stage while realizing its strategic vision of "Rooted in Taiwan, Outreaching the World."
During her presentation, Sarina highlighted that Honeybear Biosciences' core CoNectar® proprietary glycan conjugation platform has been granted patents in the United States, Japan, Taiwan, and other countries, establishing a strong intellectual property foundation for the company's global drug development strategy. From a business perspective, Honeybear Biosciences has adopted a dual-track approach that combines proprietary drug development with technology licensing and strategic partnerships. Upstream, the company collaborates with Singapore's A*STAR and the University of California, San Francisco (UCSF) to advance innovative research, while downstream it has
partnered with the world-renowned Memorial Sloan Kettering Cancer Center (MSKCC) to accelerate preclinical development and clinical translation.
In addition, Honeybear Biosciences has assembled a highly experienced team with professionals from leading multinational pharmaceutical companies, including Novartis, Amgen, Pfizer, and Gilead. The company has also established a distinguished international advisory board comprising the 2029 President of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and former U.S. Food and Drug Administration (FDA) officials, ensuring alignment with global regulatory requirements and manufacturing standards.
Within just over two years, Honeybear Biosciences is on track to complete the Investigational New Drug (IND) application for its first ARC candidate, HB001, and plans to initiate Phase I clinical trials in the United States and Australia. "We will continue to strengthen the global impact of Taiwan's innovative biopharmaceutical industry and bring Taiwan-developed breakthrough therapies to the international stage," said Sarina Lin with confidence.
Honeybear Biosciences has been dedicated to the development of next-generation Antibody-Drug Conjugates (ADCs) and Antibody-Radionuclide Conjugates (ARCs) by integrating the expertise of internationally renowned, cross-disciplinary scientists and industry experts. On July 16, 2026, during BioAsia, Sarina Lin, Vice Chairwoman and General Manager, was invited to speak at the International Market Expansion Forum for Biomedical Startups, where she shared Honeybear Biosciences’ experience in global market expansion and discussed the company’s international growth strategy and achievements.
Facing an increasingly competitive global biopharmaceutical landscape, Honeybear Biosciences has adopted a global market-oriented strategy from its inception. Leveraging its proprietary technology platform, a world-class international advisory team, multi-channel clinical collaborations, and active participation in leading global biotechnology conferences, the company has enhanced its international visibility through scientific presentations, business partnering activities, and targeted media outreach. These efforts have brought both Honeybear Biosciences and its award-winning CoNectar® proprietary platform to the attention of the global biotechnology community, enabling the company to expand onto the international stage while realizing its strategic vision of "Rooted in Taiwan, Outreaching the World."
During her presentation, Sarina highlighted that Honeybear Biosciences' core CoNectar® proprietary glycan conjugation platform has been granted patents in the United States, Japan, Taiwan, and other countries, establishing a strong intellectual property foundation for the company's global drug development strategy. From a business perspective, Honeybear Biosciences has adopted a dual-track approach that combines proprietary drug development with technology licensing and strategic partnerships. Upstream, the company collaborates with Singapore's A*STAR and the University of California, San Francisco (UCSF) to advance innovative research, while downstream it has
partnered with the world-renowned Memorial Sloan Kettering Cancer Center (MSKCC) to accelerate preclinical development and clinical translation.
In addition, Honeybear Biosciences has assembled a highly experienced team with professionals from leading multinational pharmaceutical companies, including Novartis, Amgen, Pfizer, and Gilead. The company has also established a distinguished international advisory board comprising the 2029 President of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and former U.S. Food and Drug Administration (FDA) officials, ensuring alignment with global regulatory requirements and manufacturing standards.
Within just over two years, Honeybear Biosciences is on track to complete the Investigational New Drug (IND) application for its first ARC candidate, HB001, and plans to initiate Phase I clinical trials in the United States and Australia. "We will continue to strengthen the global impact of Taiwan's innovative biopharmaceutical industry and bring Taiwan-developed breakthrough therapies to the international stage," said Sarina Lin with confidence.
Vice Chairwoman and General Manager Sarina Lin gave a lively and engaging talk on Honeybear Biosciences' international expansion experience.
